Brodalumab a Successful, Safe Treatment Option for Nail Psoriasis
The efficacy of brodalumab for the treatment of nail psoriasis is assessed.
The efficacy of brodalumab for the treatment of nail psoriasis is assessed.
Do steroids induce severe psoriasis flares at significant rates in a general psoriasis population?
Time to, and predictors of, relapse in patients with psoriasis who responded to tildrakizumab then were assigned to placebo were reported.
The effectiveness of ustekinumab and secukinumab in the treatment of psoriasis was assessed.
The efficacay and safety of 2 secukinumab dosing regimens in a pediatric population with severe chronic plaque psoriasis were evaluated.
A case report of a man with plaque psoriasis and comorbidities that include psoriatic arthritis and ulcerative colitis.
Early efforts to characterize the efficacy of treatment of psoriasis with ustekinumab in pediatric patients are reviewed.
VCAM-1 and E-selectin levels and their relationship with psoriasis severity were evaluated.
A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.
Long-term efficacy and safety of proactive psoriasis management
with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for plaque psoriasis was assessed in a novel trial.